The UKMS Pharmacy Group was established in the Summer of 2021, with the inaugural meeting of the core steering group taking place in January 2022.

The aim of the Group is to promote excellence in the pharmaceutical care of patients with myeloma.

It will support education, development of guidelines and encourage cancer pharmacists to undertake high quality, audit and research (aligned with UKMS and UK MRA workplans).  The group will aim to support standardisation of clinical pharmacy practice across the UK.   Initial areas of focus will be the use of direct oral anticoagulants as imid thromboprophylaxis and the use of bile acid sequestrants for lenalidomide induced diarrhoea.  Other areas of focus will be delivering myeloma treatments at home and producing standardised medicine administration charts to support patients with complex myeloma treatments.

The Group will also establish a network of pharmacists with a specialist interest in myeloma across the UK. This will provide increased opportunity for peer support and encourage sharing of good clinical practice.